Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118365 · ClinicalTrials.gov registry record · Phase 3
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT00118365: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00118365 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 375 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118365, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG sulindac
- DRUG eflornithine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 1998-07 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118365
The ClinicalTrials.gov registry entry for NCT00118365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00118365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118365 about?
NCT00118365 is a clinical study titled "Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps". This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithi...
What is the current status of trial NCT00118365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 1998-07. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00118365?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), sulindac (DRUG), eflornithine (DRUG).
Who is sponsoring clinical trial NCT00118365?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.